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ABSTRACT
In an attempt to abrogate the deleterious effects of graft-versus-host disease (GVHD), allogeneic transplan-
tation for nonmalignant diseases was performed using high-dose CD34-cell infusion, partial T cell depletion,
and no posttransplantation GVHD prophylaxis. Between 1998 and 2004, 16 patients with matched related
donors were treated. Median age was 1.5 years (range, 5 months-18 years). The conditioning regimen
consisted of busulphan 16 mg/kg, cyclophosphamide 200 mg/kg, antithymocyte globulin (ATG) 25 mg/kg, and
fludarabine 200 mg/m2. No GVHD prophylaxis was given. High doses of CD34 cells, positively selected by
immunomagnetic beads, were infused at a median dose of 10.7  106 CD34/kg (range, 7.4-50  106). A total
of 1  105/kg T cells were given. All patients engrafted, with no graft rejections. All were alive and well at a
median of 37 months posttransplantation (range, 18-89 months). Only 1 patient developed chronic GVHD. No
episodes of severe infection occurred during or after transplantation. Immunologic reconstitution with CD3/
CD4 T cells > 200/L was observed at a median of 117 days and that with naive T cells (CD4/CD45RA) at a
median of 188 days posttransplantation. Our findings suggest that allogeneic transplantation from a matched
family donor for nonmalignant disorders can be successfully performed using high doses of CD34 cells,
moderate T cell depletion, and no posttransplantation immunosuppression.
© 2007 American Society for Blood and Marrow Transplantation
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(NTRODUCTION
Allogeneic stem cell transplantation (SCT) is used
o treat many diverse nonmalignant inherited diseases,
uch as blood diseases (thalassemia major, sickle cell
nemia), metabolic diseases (mucopolysacharidoses,
-linked adrenoleucodystrophy [X-ALD]), immuno-
eﬁciency states, and others. The purpose of alloge-
eic transplantation in these diseases is to correct the tasic defect by repleting stem cells capable of produc-
ng the deﬁcient component (ie, hematopoietic cells,
ymphocytes, or enzymes). In such situations, T cells
re needed to facilitate engraftment and immunologic
econstitution, but, because of the nature of the basic
efect, which is not malignant, no graft-versus-tumor
GVT) effect is needed [1].
Despite improved immunosuppressive regimens
hat are used posttransplantation, acute and chronic
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R. Elhasid et al.330raft-versus-host disease (GVHD) continues to be a
ajor cause of morbidity and mortality after alloge-
eic SCT [2]. T cell depletion of donor marrow is the
ost effective approach for reducing or eliminating
oth acute and chronic GVHD. On the other hand, it
an hamper engraftment [3] and cause delay in immu-
ological reconstitution [4], making the patient vul-
erable to infection. In addition, the incidence of
pstein-Barr virus–associated B cell lymphoprolifera-
ive disorders (EBV-LPD) is known to be increased in
his patient group [5,6].
Several publications [7-9] have reported that mod-
rate T cell depletion—to a ﬁnal concentration of 105
cells/kg—given in the setting of a matched related
ransplantation could abrogate GVHD, without the
eed for posttransplantation immune suppression, and
ith no adverse impact on engraftment. This meth-
dology also has been successful in chronic myeloge-
ous leukemia [10]. The use of granulocyte colony-
timulating factor (G-CSF) to mobilize peripheral
lood stem cells (PBSCs) offers the possibility of
ransfusing a high number of CD34 cells, thereby
iminishing the risk of graft failure [11]. Moreover,
voiding the use of cyclosporine or other immunosup-
ressive agents posttransplantation will prevent toxic-
ty, including a delay in immune recovery. Such a
ransplant would be offered only in those instances in
hich GVHD is not associated with therapeutic ben-
ﬁts, as in nonmalignant disorders.
In view of the theoretical and the reported beneﬁts
f moderate T cell depletion and no posttransplanta-
ion immunosupression, we adopted this therapeutic
pproach in 1998 for patients with nonmalignant dis-
rders. Presently, we retrospectively reviewed the
linical records of 16 consecutive patients who under-
ent transplantation for nonmalignant diseases. The
ransplantation method included the administration of
igh doses of CD34 cells from matched related do-
ors, performing moderate T cell depletion (105/kg)
y positive selection of CD34 cells with immuno-
agnetic beads, and avoiding immunosuppressive
herapy posttransplantation.
ATIENTS AND METHODS
atients
A total of 16 patients requiring peripheral blood
tem cell transplantation (PBSCT) for nonmalignant
isorders were treated at the RambamMedical Center
n Haifa, Israel, between 1998 and 2004. Eligibility
riteria included nonmalignant disorder requiring al-
ogeneic transplantation and the availability of a
atched related donor. Patients with thalassemia ma-
or were eligible only if they had class 1 disease [12].
The median age was 1.5 years (range, 5 months-18ears). Six patients had thalassemia major (all class 1), ind 3 had immunodeﬁciency, 2 with x-linked lympho-
roliferative syndrome (XLP) and 1 with severe con-
enital neutropenia associated with infantile osteopo-
osis and multiple bone fractures. Further data
egarding the speciﬁc bone disease of the latter patient
ave been published previously [13]. Three patients
ad metabolic disorders (2 with Hurler syndrome, 1
ith Sanﬁllipo A), 1 had X-ALD, 2 had familial he-
ophagocytic lymphohistiocytosis (FHL), and 1 had
hronic granulomatous disease (CGD).
All parents received detailed explanation regard-
ng the foregoing therapeutic approach and of the
lternative conventional conditioning regimen with-
ut T cell depletion and with the use of GVHD
rophylaxis. They all signed an informed consent.
he patient who underwent transplantation for CGD
as age 18 years and also signed the informed consent.
onditioning Regimen
The planned conditioning regimen consisted of
ral busulphan 4 mg/kg on days 9, 8, 7, 6;
yclophosphamide 50 mg/kg on days 5, 4, 3,
nd 2; antithymocyte globulin (ATG; Fresenius,
rafelﬁng, Germany) 5 mg/kg on days 9, 8, 7,
6, and 5; and ﬂudarabine 40 mg/m2 on days 9,
8, 7, 6, and 5. This regimen was given to 15
atients, the 1 exception being the patient with severe
ongenital neutropenia and bone disease who received
educed doses of chemotherapy because of severe fail-
re to thrive and status post–right middle lobe resec-
ion secondary to a previous Aspergillus infection. In
his patient, the doses were reduced to busulphan 4
g/kg/day for 3 days, cyclophosphamide 60 mg/kg
or 2 days, and ﬂudarabine 30 mg/m2 for 5 days.
yclosporine A 1 mg/kg was given to all patients
uring conditioning on days 8 to 1, to prevent or
meliorate a cytokine storm [14]. No GVHD prophy-
axis was given posttransplantation.
Oral busulphan dose was targeted using area un-
er the concentration-time curve (AUC) calculation
15], and dosage adjustments were made according to
lood levels. Target value for the busulphan dose
djustments was 1150 mol/minute. Patients who had
ifﬁculty taking the prescribed dose were given it
hrough a nasogastric tube.
Premedication before ATG administration in-
luded i.v. solomedrol 1 mg/kg as well as paracetamol
5 mg/kg and phenergan 0.5 mg/kg. All ATG doses
ere given as prescribed.
onors
All donors were HLA-identical at the HLA-A, -B,
DRB1, and -DQB1 loci with their respective recipi-
nts. HLA class I analysis was performed using sero-
ogic methods, whereas class II analysis was done us-
ng high-resolution molecular methods. Donors were
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T Cell Depleted BMT in Nonmalignant Disease 331ither siblings (14/16) or uncles (2/16). All received
ubcutaneous G-CSF at a dose of 10 g/kg, adminis-
ered daily for 5-6 consecutive days. A second aphere-
is procedure was performed if the ﬁrst one resulted in
he collection of fewer than 7.0 106 CD34 cells/kg
f the recipient’s body weight.
The median age of donors was 9.5 years (range,
-37 years). Of the 16 donors, 3 required 2 days of
pheresis, and 13 required 1 day only. Four of the 16
onors complained of bone pain while receiving G-
SF, which was easily controlled with oral analgesia.
ix of 16 donors required femoral line insertion for
he procedure. All donors tolerated the procedure
ell, and none required any transfusion.
agnetic-Activated Cell Separation (MACS)
T cell depletion was performed by positive selec-
ion of CD34 cells by immunomagnetic beads (Milte-
yi Biotech, Bergisch Gladbach, Germany). On day 0,
igh doses of CD34 cells were infused with a median
ose of 10.7  106 CD34/kg (7.4-l50  106). T cells
ere added to achieve a ﬁnal concentration of 1 105
D3 cells/kg.
himerism Testing
Blood samples for chimeric status were studied at
everal time points posttransplantation: 2 months, 6
onths, 1 year, and every year thereafter. DNA was
xtracted from peripheral blood using the Qiagen
NA Blood kit (QIAamp DNA Blood Mini Kit) ac-
ording to the manufacturer recommendations. Chi-
erism of subpopulations of cells was not analyzed.
Chimerism testing was based on short tandem
epeat–polymerase chain reaction (STR-PCR) analy-
is using the AmpFlSTR SGM Plus (Applied Biosys-
ems, Foster City, CA). The following loci were
mpliﬁed: D3S1358, vWA, D16S539, D2S1338,
melogenin, D8S1179, D21S11, D18S51, D19S433,
HO1, and FGA. The PCR fragments were detected
ith an ABI Prism 310 Genetic Analyzer and analyzed
sing the Gene Scan software (Applied Biosystems).
he software allows for an easy determination and
abeling of the informative STRs of the pretransplan-
ation donor and recipient samples. The results can be
ompared with the posttransplantation samples.
tatistical Analysis
The data were analyzed using SPSS software ver-
ion 12. The Pearson correlation was used to demon-
trate the correlation between absolute number of
D3/CD4 T cells and time posttransplantation
days), the relation between chimeric status and he-
oglobin levels in thalassemic patients, and the rela-
ion between chimeric status and the CD34 cell dose
nfused. Values of absolute numbers of CD3/CD4 and dD4/CD45RA T cells above 200 and 400 were rep-
esented by descriptive statistics (median, range).
ESULTS
ngraftment
Neutrophil engraftment ( 0.5 109/L) occurred
t a median of 10 days posttransplantation (range,
-13 days). Platelet transfusion independence ( 20
09/L) occurred at a median of 20 days posttransplan-
ation (range, 11-34 days). There were no graft rejec-
ions.
himerism
Three patients had full donor chimerism, 1 with
halassemia major, 1 with ALD, and 1 with chronic
ranulomatous disease (Table 1). These patients re-
eived 20.7  106/kg, 7.4  106/kg, and 18  106/kg
D34 cells, respectively. Stable mixed donor chimer-
sm was documented in all other patients. CD34 cells
iven were between 8 and 50  106 per kg. Three
atients had stable donor chimerism  50%, 1 with
urler syndrome (39%), 1 with Sanﬁllipo disease
42%), and 1 with thalasemia major (29%). They
eceived 10 106/kg, 33 106/kg, and 10.7 106/kg
D34 cells, respectively. There was no statistically
igniﬁcant correlation between the degree of chimer-
sm posttransplantation and the CD34 cell dose in-
used (r 0.038; P .89). No rejection occurred, and
ll these patients are well.
linical Outcome
All patients are alive and well at a median of 37
onths posttransplantation (range, 18-89 months).
etailed clinical outcome of each patient is given in
able 2.
oxicity
GVHD. None of the patients developed acute
VHD (aGVHD). Only 1 patient with thalassemia
ajor developed extensive chronic GVHD (cGVHD)
ccording to Seattle group grading scheme, including
eneralized skin involvement and oral mucosa [16];
his was treated successfully with cyclosporine A, low
oses of prednisone, and photopheresis.
Veno-occlusive disease. Three patients developed
eno-occlusive disease (VOD), 1 with thalassemia ma-
or and 2 with FHL. These patients were treated with
eﬁbrotide and recovered fully.
Capillary leak syndrome. This developed in 4 pa-
ients (3 patients with thalassemia major and 1 patient
ith XLP) during engraftment. The patients were
reated with high-dose steroids (solomedrol 30 mg/
g/day for 3 days, tapering by half every 3 days), and
iuretics. Two patients underwent paracentesis be-
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R. Elhasid et al.332ause of compartment syndrome. All recovered and
re well.
Infections. All patients, as expected, developed fe-
rile neutropenia. However, no clinically severe infec-
ions occurred during or after transplantation. One
atient with XLP developed cytomegalovirus (CMV)
neumonia in the ﬁrst month of hospitalization; this
as diagnosed by a positive PCR from bronchoalveo-
ar lavage; he was treated with foscarnet and later
anciclovir and recovered fully. All patients were fol-
owed up for CMV reactivation using PCR analysis
nd an antigenemia assay every week. In case of
eactivation, preemptive therapy with ganciclovir
as started. Reactivation of CMV occurred in 5
atients, on days 25, 47, 48, 54, and 79 posttrans-
lantation, and all were treated successfully with
reemptive ganciclovir.
Autoimmune complications. Autoimmune complica-
ions occurred in 2 patients. One patient with thalas-
emia major developed autoimmune hemolytic anemia
n day 45 posttransplantation and was successfully
reated with steroids. Both the donor and recipient
ad blood type O, and the autoimmune hemolytic
nemia was diagnosed by a positive direct antiglobulin
est (Coombs’ test) for C3 and IgG and a high lactate
ehydrogenase level of 1001 /L (normal range, 60-
able 1. Transplantation Engraftment
Patient Diagnosis
Age at
Transplantation
CD34 
106/kg
Follow
(mont
1 Thalassemia
major
1 year 9.7 50
2 Thalassemia
major
9 months 8 32
3 Thalassemia
major
22 months 10.7 33
4 Thalassemia
major
22 months 10 27
5 Thalassemia
major
4 years 8.1 25
6 Thalassemia
major
5 years 20.7 72
7 Congenital
neutropenia,
bone disease
11 months 19.4 89
8 XLP 1 year 50 73
9 XLP 8 years 23 47
10 CGD 18 years 18 26
11 Hurler’s
syndrome
1.5 years 32 70
12 Hurler’s
syndrome
11 months 10 37
13 Sanfillipo A 3 years 33 40
14 X-ALD 8 years 7.4 36
15 FHL 5 months 8.6 37
16 FHL 8 months 18.6 18
D indicates no data.
blank cell means that the patient has not reached that time in th25 /L). Another patient with FHL developed auto- dmmune thrombocytopenia on day 35 posttransplan-
ation that resolved with intravenous immunoglobulin
nd steroid therapy. Interestingly, they both had mixed
himerism, the patient with thalassemia had 52% donor
ells, whereas the patient with FHL had 78% donor
ells.
osttransplantation Lymphoproliferative Disease
No patient developed posttransplantation lym-
hoproliferative disease.
mmunologic Reconstitution
Immunologic reconstitution was followed by mea-
urement of the CD3/CD4 T cell content every
onth posttransplantation. The subpopulations of T
ells were determined by ﬂow cytometry using ﬂuo-
escent-conjugated monoclonal antibodies (BD Bio-
ciences, Franklin Lakes, NJ) and analysis on gated
ymphocytes using FACScalibur (Becton Dickinson,
ranklin Lakes, NJ). A linear correlation was observed
etween the recovery of CD3/CD4 T cells and the
ime after transplantation (days) (P  .0001, r  0.68;
igure 1). CD3/CD4 T cells  200/L occurred at a
edian of 117 days posttransplantation (range, 47-190
Chimerism: Percent Donor Cells
ay 20-60 Day 60-180 Day 180-365 1-3 years > 3 years
69 ND 59 50 52
ND 100 72 67
60 ND ND 29
100 ND 100
90 65 ND 56
ND ND ND ND 95
75 30 ND 37 50
100 80 ND 80
50 ND 47 81 81
100 ND 100
ND ND ND 34 65
88 50 26 39
61 ND 52 42
100 ND 80 100
96 82 78
76 75 68
-up.-up
hs) Days). CD3/CD4 T cells  400/L occurred at a
Table 2. Patient Characteristics and Response to Treatment
Patient Age Diagnosis Clinical Manifestations Pretransplantation Outcome Posttransplantation
1 1 year Thalassemia major Blood transfusion every 3 weeks Stable hemoglobin 11gr%
2 9 months Thalassemia major Blood transfusion every 3 weeks Stable hemoglobin 10gr%
3 22 months Thalassemia major Blood transfusion every 3-4 weeks Stable hemoglobin 12gr%
4 22 months Thalassemia major Blood transfusion every 3-4 weeks Stable hemoglobin 12.5gr%
5 4 years Thalassemia major Blood transfusion every 3-4 weeks Stable hemoglobin 11.5gr%
6 5 years Thalassemia major Blood transfusion every 3-4 weeks Stable hemoglobin 11gr%
7 11 months Congenital neutropenia,
bone disease
Pancytopenia, hypogammaglobulinemia, bone disease Pancytopenia and hypogammaglobulinemia resolved; persistent
bone disease
8 1 year XLP Three brothers died of fulminant EBV infection Alive and well 39 months posttransplantation; no IVIG treatment
9 8 years XLP Brother and 3 cousins died of fulminant EBV infection; IVIG treatment Alive and well 24 months posttransplantation; no IVIG treatment
10 18 years CGD Recurrent Staphylococcus aureus abscess granulomas in lung and liver;
absence of oxygen burst in white blood cells
All resolved; normal oxygen burst
11 1.5 years Hurler’s syndrome External hydrocephalus; coarse facial features; involvement of mitral
and aortic valves; hepatosplenomegaly; high urine MPS; corneal
opacity; psychomotor developmental delay
All resolved; progression in corneal opacity; developmental
milestones achieved
12 11 months Hurler’s syndrome Hydrocephalus; hepatosplenomegaly; congestive heart failure; severe
mitral regurgitation; coarse facial features; high urine MPS;
psychomotor developmental delay
Resolved; improved mitral valve function; decreased facial
dysmorphism; developmental milestones achieved
13 3 years Sanfillipo A Increased urinary MPS; hepatomegaly; hypotonia Increased urinary MPS and hepatomegaly resolved; hyperactivity,
unsteady gait
14 8 years X-ALD Abnormal serum VLCFA pattern; neurologic asymptomatic MRI:
leukodystrophy; low score (>10) with gadolinium enhancement
Resolved; neurologic deterioration; no further progression of
leukodystrophy; no gadolinium enhancement
15 5 months FHL Fever; hepatosplenomegaly; liver test abnormalities; impaired
coagulation tests
All resolved
16 8 months FHL Fever; hepatosplenomegaly; liver test abnormalities; sibling death
resulting from FEL
All resolved
IVIG indicates intravenous immunoglobulin; VLCFA, very-long-chain fatty acid.
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R. Elhasid et al.334edian of 153 days posttransplantation (range, 68-261
ays).
Reconstitution of naive T cell (CD4/CD45RA)
nd CD4/CD45RO was measured in 10 of the 16
atients (Figure 2). The ﬁrst 6 patients were not ex-
mined because of the lack of the speciﬁc monoclonal
ntibody at this time. The number of naive T cells
ncreased gradually after transplantation (Figure 2),
ising to  200/L at a median of 188 days (range,
1-334 days) posttransplantation.
ISCUSSION
In an attempt to abrogate the deleterious effects of
VHD, allogeneic transplantation for nonmalignant
iseases was performed using high-dose CD34 pro-
enitor cell infusion, partial T cell depletion, and no
osttransplantation GVHD prophylaxis. It is well
nown that T cell depletion is associated with de-
reased GVHD; it is also associated with a higher rate
f graft failure, increased risk of leukemic relapse, and
he development of EBV-LPD [3,5]. Immune recon-
titution is also delayed, thus exposing the patient to
igure 1. Linear correlation between absolute number of CD3/CD
ere obtained from 16 patients. A signiﬁcant correlation was found
osttransplantation (P  .0001; r  0.68).evere viral and opportunistic infections. On the other sand, recipients of unmodiﬁed HLA-identical sibling
arrow that receive on the order of 1-2  107
cells/kg recipient body weight, with no prophylactic
osttransplantation immunosuppression, experience
n approximate 80%-100% incidence of grade II–IV
GVHD [17]. It has been demonstrated that recipi-
nts of HLA-identical T cell–depleted marrow who
eceived no posttransplantation immunosuppression
ere protected from clinically signiﬁcant aGVHDwhen
he marrow graft contained  1  105 T cells/kg
ecipient body weight [7-9].
Based on such data, it was decided to perform an
llogeneic PBSCT from a matched sibling donor
sing moderate T cell depletion (105/kg T cells) by
eans of positive selection of CD34 cells, thus
voiding both the occurrence of GVHD and the
eed for immunosuppression posttransplantation.
his method has been used successfully in 31 patients
ith chronic myeloid leukemia [10], of whom 29 en-
rafted with neutrophil recovery on posttransplanta-
ion day 11 and platelet recovery on day 19. The other
patients engrafted promptly on autologous rescue.
osttransplantation CMV infection was short and re-
lls and time of posttransplantation (days). A total of 94 blood tests
en the absolute number of CD3/CD4 T cells/L and time (days)4 T ce
betweponded to a brief course of preemptive therapy.
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T Cell Depleted BMT in Nonmalignant Disease 335GVHD (grade 1-2) developed in 7 patients and was
reated successfully.
Another study used highly puriﬁed peripheral
lood CD34 progenitor cells from related and un-
elated donors in 25 children with nonmalignant dis-
ase to prevent acute and cGVHD and reduce trans-
lantation-related mortality (TRM) [18]. The patients
eceived a median of 12.9  106 CD34 progenitor
ells with a median of 6.1103 contaminating T lym-
hocytes/kg body weight; they received no posttrans-
lantation immunosuppression. Engraftment occurred
nitially in 21 of 25 patients. No aGVHD grade II was
een; 19 patients were free of disease or progression,
ut 11 required donor T cell infusions because of
ncreasing autologous chimerism.
In comparison, the patients in our study received a
igher dose of T cells in the graft (105/kg); all patients
ngrafted, and none required T cell add-back. Only 1
f the 16 patients developed cGVHD, and all are
urrently alive and either free of disease or stabilized.
To facilitate engraftment in the presence of mod-
rate T cell depletion, high doses of CD34 cells (me-
ian dose, 10.7  106/kg) were given. High-dose infu-
ion of CD34 hematopoietic progenitors has been
hown to abrogate resistance to engraftment and can
ven overcomemajor histocompatibility barriers in bone
arrow transplantation (BMT) [11,19,20]. Indeed, all of
ur patients engrafted at a median of day 10 posttrans-
lantation. Thus, the combination of high-dose
D34 cells in the presence of moderate T cell de-
letion was successful in promoting engraftment with
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igure 2. Circulating CD3/CD4, CD4/CD45 RA, and CD4/CD45 RO
umber of CD3/CD4 and CD4/CD45RA T cells over time. The v
rom 16 patients. The numbers of blood samples taken at each timo rejection thereafter. mThis protocol was chosen in patients with nonma-
ignant disorders in an attempt to avoid GVHD with-
ut compromising the safety and efﬁcacy of transplan-
ation. GVHD remains a major complication of
llogeneic BMT and a predictor for morbidity and
ortality. Up to 30% of the recipients of SCT or
MT from HLA-identical related donors and most
atients who receive cells from other sources will
evelop  grade 2 acute GVHD (aGVHD) despite
mmunosuppressive prophylaxis [21]. For chronic
VHD, the 3-year risk of TRM is 28% if limited and
8% if extensive [22]. In patients with malignant dis-
rders, T cells are especially needed for the GVT
ffect, and although more chronic GVHD may occur
ith peripheral stem cells as opposed to bone marrow
tem cells, the event-free survival was also better be-
ause of the graft-versus-leukemia effect [23]. Another
tudy compared the results of 143 PBSCTs and 630
MTs from HLA-identical sibling donors in children
ged 8-20 years with acute leukemia [24]. Hematopoi-
tic recovery was faster after PBSCT. Risks of grade
I-IV acute GVHD were similar, but the risk of
hronic GVHD was higher after PBSCT. No T cell
epletion was done in those patients. Although TRM
as higher after PBSCT, the only signiﬁcant differ-
nce in causes of mortality between PBSCT and BMT
ecipients was in the proportion of deaths related to
VHD occurring more than 100 days posttransplan-
ation: 20% in the PBSCT group and 5% in the BMT
roup (P  .0007). Because all of our patients under-
ent T cell depletion and none developed aGVHD, it
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R. Elhasid et al.336ill not cause higher mortality compared with BMT.
ndeed, all patients survived at a median follow-up of
7 months.
In inborn errors of metabolism, such as Hurler’s
yndrome, GVHD can further increase toxicity. In a
eport on Hurler’s syndrome, the probability of grade
I-IV aGVHD at 100 days was 32% for genotypically
dentical sibling transplantation recipients. Children
ho developed aGVHD of grade II or worse had
igniﬁcantly poorer cognitive outcome [25].
The incidence and risk factors for GVHD after
MT in thalassemia were analyzed in 724 patients for
GVHD and in 614 patients for cGVHD. The overall
ncidence of grade II-IV aGVHD was 26.9%; that of
rade III-IV aGVHD was 13.5%. Class 1, class 2, and
lass 3 patients had aGVHD indicences of 27%,
2.4%, and 20.7%, respectively. Mortality in class 1
atients with grade III-IV aGVHD was 27.3%. The
ncidence of cGVHD was 27.3%. The incidence of
GVHD was 22% in class 1, 30.6% in class 2, and
6.9% in class 3. The probability of cGVHD at 2
ears after BMT was 32% in patients with grade I
GVHD, 53% in those with grade II aGVHD, and
4% in those with grades III-IV aGVHD [26]. These
ndings indicate that GVHD is a major complication
f HLA-identical related BMT for thalassemia. Fu-
ure studies on more effective strategies for preventing
VHD are needed, particularly in a thalassemia BMT
etting, where a desirable antileukemic effect of
VHD does not exist.
Another feature of this protocol is the lack of
osttransplantation GVHD prophylaxis (although the
TG given as part of the conditioning regimen may
irculate for some time posttransplantation and pro-
ide some protection from GVHD). Others have
emonstrated, by measuring residual ATG capable of
inding to lymphocytes after transplantation, that al-
hough the actual mean half-life of ATG was 6.8 days
range, 2.4-14 days), a mean time of 46 days (range,
4-91 days) was required for ATG levels to decay to
ackground [27]. The toxicity of cyclosporine (CsA)
iven to prevent GVHD was avoided in our patients.
n a retrospective analysis of neurotoxicity in 625
ecipients who underwent transplantation for thalas-
emia and given CsA as part of GVHD prophylaxis,
he overall neurotoxicity was 28%, and the incidence
f convulsions was 10%. Neurologic ﬁndings were
eversible after temporary reduction or discontinua-
ion of CsA [28]. Avoiding CsA in BMT for cerebral
-ALD is probably even more important. The inci-
ence of severe (grade III-IV) aGVHD was 17% in
ecipients of related donor hematopoetic SCT
HSCT) analyzed from the international HSCT ex-
erience from 1982 to 1999. Severe aGVHD can be
ssociated with rapid, profound clinical deterioration
n these patients [29]. Because many factors can affect
eurologic outcomes in boys with advanced cerebral s-ALD, including the clinical course after HSCT, an
ffort should be made to avoid neurotoxic drugs as
ell as GVHD.
Another obstacle to successful transplantation us-
ng T cell–depleted grafts is the delayed immune
ystem recovery [4], higher incidence of CMV reacti-
ation [30], and increased risk of posttransplantation
BV-LPD [5,6]. No severe infections (including no
evere CMV infections) occurred in our patients. No
BV-LPD disorder occurred. We presume that the
arefully controlled incomplete T cell depletion used
n this protocol contributed to these ﬁndings.
VOD of the liver occurred in 3 patients, 1 with
halassemia major and 2 with FHL. VOD was a sig-
iﬁcant complication in a retrospective analysis of the
utcome of BMT in 48 consecutive patients with FHL
31]. It occurred in 28% of cases, more frequently
fter haploidentical HSCT and in patients under age
2 months at transplant who received ATG in a con-
itioning regimen.
Immunologic reconstitution with 200/LCD3/
D4 T cells occurred at a median of 117 days post-
ransplantation. Naive T cells (CD4/CD45RA) were
200/L at a median of 188 days posttransplanta-
ion. A study on adult patients comparing immune
econstitution after allogeneic BMT and PBSCT
ound that both naive and memory CD4T cells were
ore abundant in PBSCT [32]. Total CD4 T cells
ere  200/L in about 100 days post-PBSCT,
hereas naive T cells were  100/L about 200 days
ost-PBSCT. No T cell depletion was performed in
hese transplantations. Recovery of naive CD4 T cells
as at least as rapid in our patients despite the pres-
nce of T cell depletion. The avoidance of cyclospor-
ne posttransplantation and the absence of GVHD in
ur patients also probably contributed to the more
apid immune recovery.
More graft rejection was documented in T cell–
epleted transplantations [3]. Our patients experi-
nced rapid engraftment at a median of 10 days, with
o graft rejection thereafter. Nevertheless, 13 of the
6 patients experienced mixed chimerism. When SCT
s done to treat malignant hematologic disorders,
easurement of chimeric status may indicate early
elapse and, in aplastic anemia, graft rejection [33].
CT for nonmalignant hematologic disorders does
ot require complete donor chimerism for a successful
utcome. The evolution of persistent mixed chimer-
sm was studied in 55 patients who underwent trans-
lantation for thalassemia [34]. Rejection occurred in
0 patients, the host component disappeared in 20,
nd mixed chimerism without transfusion require-
ents persisted for 1-7 years in the remaining 15. In
patients with stable mixed chimerism for 4, 5, and 7
ears, host hematopoiesis ﬂuctuated between 25% and
5%. Despite this, donor beta-globulin chain synthe-
is maintained hemoglobin levels of 10-13.5 g/dL
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T Cell Depleted BMT in Nonmalignant Disease 337ithout transfusion. It is noteworthy that in the afore-
entioned report, most patients underwent transplan-
ation for class III thalassemia [35], which may explain
he relatively high rate of rejection and graft failure
n the patients with mixed chimerism. Among our
atients, 5 of 6 patients who underwent transplanta-
ion for thalassemia major developed mixed chimer-
sm. All patients underwent transplantation for class I
halassemia; all were transfusion-independent with
table graft at a median of 32 months (range, 25-72
onths) posttransplantation. There was no correla-
ion between chimeric status and hemoglobin levels in
hose patients (Figure 3). Only the donor of patient 2
ad thalassemia minor; all other donors had no thalas-
emia. The hemoglobin level was determined by the
tatus of the donor (with or without thalassemia mi-
or), not by the chimeric status. Correction of anemia
n thalassemia major, as well as different enzymes in
ther metabolic diseases, occurred in the presence of
ixed chimerism in our patients. We cannot exclude
he possibility that for patients with thalassemia and
igniﬁcant organ dysfunction, such as class III, the
stablishment of mixed chimerism may be insufﬁcient
o maintain the graft on a long-term basis.
In conclusion, although the number of patients in
ur study was relatively low, the experience described
n this report may suggest that a somewhat novel
pproach should be considered in managing patients
ndergoing SCT from a matched family donor for a
onmalignant disease. This is achieved using high-
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igure 3. Chimeric status and hemoglobin values in 6 patients wit
evels during follow-up after transplantation. No correlation was fou
osttransplantation (P  .86).ose CD34-cell infusion, moderate T cell depletion,nd no immunosuppression posttransplantation. In
ur patients, this method was efﬁcacious, led to
rompt engraftment, minimal GVHD and other tox-
cities, and excellent long-term results. Ultimately, if
onﬁrmed by controlled studies, this approach may be
onsidered the option of choice for patients with non-
alignant disorders in whom GVHD is not associated
ith therapeutic beneﬁt.
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